Researchers in Barcelona have identified a new biomarker, CTHRC1(+) CAFs, that can predict immunotherapy response and prognosis in colorectal cancer patients.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
New biomarker to determine whether immunotherapy may work in people with colon and rectal cancer | IRB Barcelona
Nearly 3,000 patients studied
5% immunotherapy eligibility